Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

The General Pharmaceutical Council (GPhC) have published the new guidance for prescribing weight loss injections such as ...

People will no longer be able to get weight-loss jabs after completing a simple online questionnaire as the pharmacy regulator ... to make sure jabs such as Wegovy or Mounjaro are prescribed ...

The General Pharmaceutical Council (GPhC) has introduced new rules for weight-loss jabs, such as Wegovy and Mounjaro, in ...

Medicare now covers Ozempic for millions of people with diabetes and Wegovy for a much smaller number who have both ... drugs like Eli Lilly’s Zepbound. Pharmacy benefit managers, which ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

Prescription data from IQVIA suggests Novo's obesity drug Wegovy is losing ground to rival ... Novo's 2025 sales guidance implies a 30% increase in the number of patients taking one of the ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 ... million people with Medicare prescription drug coverage used ...